Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 103 of 6351
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis is a multi-center, open-label, non-randomized, phase I/II trial. Patients with refractory or relapsed T-cell malignancies will receive autologous, prior-HSCT donor-derived or new donor-derived CD7 CAR T cells according to their HSCT history, peripheral blood leukemia burden …
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New CAR t therapy targets Hard-to-Treat myeloma
Disease control Recruiting nowThe purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Phase 2 • Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
Can a new drug combo outsmart breast cancer that resists current therapy?
Disease control Recruiting nowICARUS-BREAST02 is an open-label, multicenter, phase 1b/2, platform study that aims to evaluate the safety, tolerability, and efficacy of HER3-DXd monotherapy and in combination with other anti-cancer agents in patients with ABC. The first 2 modules will evaluate: i. safety and …
Phase 1/2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can removing the prostate boost drug therapy in advanced cancer?
Disease control Recruiting nowThe goal of this clinical trial is to compare systemic therapy combined with cytoreductive prostatectomy with standard of care (SOC) in de novo poly-metastatic hormone sensitive prostate cancer (de novo pmHSPC). The main questions it aims to answer are: 1. To explore the clinica…
Sponsor: RenJi Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Weight loss and exercise may stop knee arthritis before it starts
Prevention Recruiting nowThe goal of this study is to establish the efficacy of an intervention of dietary weight loss, exercise, and weight-loss maintenance for knee Osteoarthritis (OA) prevention in adult females aged ≥ 50 years with obesity and no or infrequent knee pain. The primary aim is to compare…
Sponsor: Wake Forest University • Aim: Prevention
Last updated Jul 25, 2026 00:00 UTC
-
Can a new vaccine shield adults from four meningitis strains?
Prevention CompletedThis is a multicenter, randomized, double-blinded, positive controlled study to evaluate the lot-to-lot consistency, immunogenicity and safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in adults aged 18 to 55 years. Subjects will be randomized to receive investiga…
Phase 3 • Sponsor: CanSino Biologics Inc. • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
New hope for rare ovarian cancer: drug combo targets tumor growth
Disease control Recruiting nowThis study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.
Phase 3 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Gene therapy offers hope for rare Blindness-Causing eye disease
Disease control OngoingThis study will evaluate and compare the safety, efficacy, and tolerability of 2 doses of a recombinant adeno-associated virus vector (AGTC-501/laruparetigene zovaparvovec )) to an untreated control group in male participants with X-linked retinitis pigmentosa caused by RPGR muta…
Phase 2/3 • Sponsor: Beacon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Magic mushroom compound psilocybin tested in major depression trial
Symptom relief OngoingApproximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybi…
Phase 3 • Sponsor: Usona Institute • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
New drug combo aims to beat tough childhood cancer
Disease control Recruiting nowThis is a phase II study to determine safety and efficacy of combining liposomal irinotecan with vincristine alternating with VAC in intermediate-risk patients, liposomal irinotecan with temozolomide and vincristine alternating with VAC in high-risk patients and the chemotherapy …
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a vaccine given during pregnancy shield infants from a deadly virus?
Vaccine CompletedThe purpose of the study is to learn about the safety and immune activity of the RSVpreF vaccine. It will be studied in infants born to mothers living with HIV. These infants may have higher chances of getting sick or dying due to RSV infection. Respiratory Syncytial Virus (RSV) …
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jul 04, 2026 00:00 UTC
-
Radioactive therapy aims to stall prostate cancer spread without hormone drugs
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. The data generated from this study will pro…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
One pill to shield the heart? a polypill aims to prevent heart failure in diabetes
Prevention Recruiting nowThis study will investigate the utility of a polypill-based strategy for patients with type 2 diabetes mellitus and high risk of heart failure (HF), as assessed via the WATCH-DM risk score. Polypill therapy will consist of empagliflozin 12.5 mg, losartan 25, 50 or 100 mg, and fin…
Phase 1/2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Prevention
Last updated Aug 06, 2026 00:00 UTC
-
Heated chemo could boost ovarian cancer survival
Disease control Recruiting nowPatients will be registered prior to, during or at the completion of neoadjuvant chemotherapy given per standard institutional guidelines +/- bevacizumab on Day 1 every 21 days for 3-4 cycles. Registered patients who progress during neoadjuvant chemotherapy will not be eligible f…
Phase 3 • Sponsor: GOG Foundation • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New shot aims to slash heart attacks in 17,300 with hidden cholesterol risk
Disease control OngoingThe purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who have cardiovascular disease or are at risk of a heart attack or stroke. The study drug will be administered subcutaneously (SC) (under…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Engineered immune cells take aim at autoimmune kidney diseases
Disease control Recruiting nowThis study is a single-center, open-label, dose-escalation exploratory clinical trial, expected to enroll 6 to 12 participants. It will use a BOIN (Bayesian Optimal Interval) design for dose escalation, with four predetermined dose groups (0.3×10\^6 cells/kg, 1.0×10\^6 cells/kg, …
Phase 1 • Sponsor: Nanjing University School of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New targeted drug shows promise in stomach cancer trial
Disease control OngoingThe purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Vaccine Recruiting nowThis clinical trial is studying the safety and efficacy of a personalized cancer vaccine called a neoantigen peptide vaccine in patients with solid tumors. These vaccines are custom-made for each patient using specific mutations (neoantigens) found in their own tumor. The goal is…
Phase 1/2 • Sponsor: Seqker Biosciences, Inc. • Aim: Vaccine
Last updated Jul 26, 2026 00:00 UTC
-
New drug sabirnetug aims to slow Alzheimer's decline
Disease control OngoingThe primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early Alzheimer's disease.
Phase 2 • Sponsor: Acumen Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for Triple-Negative breast cancer: SKB264 trial launches
Disease control Recruiting nowThe aim of the study is to evaluate the efficacy and safety of SKB264 as first-line treatment for patients with unresectable recurrent or metastatic triple-negative breast cancer (TNBC) whose tumors do not express programmed cell death ligand 1 (PD-L1) or in patients with PD-L1 p…
Phase 3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC